Effects of a novel palatinose based enteral formula (MHN-01) carbohydrate-adjusted fluid diet in improving the metabolism of carbohydrates and lipids in patients with esophageal cancer complicated by diabetes mellitus.
BACKGROUND
During perioperative management of patients with gastrointestinal cancer complicated by diabetes mellitus, adequate alimentation is required, but we often face difficulties associated with hyperglycemia and other accompanying complications. Recently, we investigated the effects of a novel palatinose based enteral formula (MHN-01) in suppressing post-prandial hyperglycemia and improving lipid metabolism in experimental animals and perioperative management of patients with esophageal cancer complicated by diabetes mellitus.


METHODS
We gave normal rats and rats with type 2 diabetes mellitus a single oral dose of fluid diet, and analyzed comparatively the time course of blood glucose level in each group until 3 h after the dose. In both the normal rat group and the type 2 diabetes group, peak blood glucose level after the MHN-01 dose was significantly lower than after a dose of ordinary fluid diet and was comparable to the peak level after a dose of a fluid diet rich in MUFA (monounsaturated fatty acid). We allowed normal mice free access to fluid diet for 43 days, and measured their body fat levels. Fat accumulation was significantly lower in mice given MHN-01 than in mice given ordinary fluid diet. We also analyzed the respiratory quotient and resting energy expenditure of normal Sprague-Dawley rats fed by MHN-01 or an ordinary fluid diet. The respiratory quotient of the MHN-01 group was significantly lower than the ordinary fluid group, although the resting energy expenditure of both groups was almost the same level. The effect of MHN-01 was estimated to be based on improvement of lipid metabolism.


RESULTS
Between 2003 and 2005, among 164 patients who underwent radical thoracic esophagectomy and/or reconstruction for esophageal carcinoma at Okayama University Hospital, nine patients (5.5%) were diagnosed with diabetes mellitus in pre-operative screening and were treated with MHN-01. Clinical courses of two cases with severe status of diabetes mellitus were presented as successful case reports of MHN-01.


CONCLUSIONS
MHN-01 was very useful in perioperative management of patients complicated by diabetes mellitus, unable to ingest food p.o. such as esophageal cancer or other diseases.
Fujiwara
Toshiya
T
Department of Gastroenterological Surgery, Transplant and Surgical Oncology, Okayama University, Okayama, Japan.
Naomoto
Yoshio
Y
Motoki
Takayuki
T
Shigemitsu
Kaori
K
Shirakawa
Yasuhiro
Y
Yamatsuji
Tomoki
T
Kataoka
Masafumi
M
Haisa
Minoru
M
Fujiwara
Toshiyoshi
T
Egi
Maritoki
M
Morimatsu
Hiroshi
H
Hanazaki
Motohiko
M
Katayama
Hiroshi
H
Morita
Kiyoshi
K
Mizumoto
Kenji
K
Asou
Takanobu
T
Arima
Hirofumi
H
Sasaki
Hajime
H
Matsuura
Motoi
M
Gunduz
Mehmet
M
Tanaka
Noriaki
N
D000368:Aged; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000178:diet therapy*; D004040:Dietary Carbohydrates / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004041:Dietary Fats / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004734:Energy Metabolism; D004750:Enteral Nutrition / Q000379:methods*; D004938:Esophageal Neoplasms / Q000150:complications / Q000178:diet therapy* / Q000601:surgery; D005229:Fatty Acids, Monounsaturated / Q000493:pharmacokinetics; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy; D007534:Isomaltose / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008875:Middle Aged; D051381:Rats; D017207:Rats, Sprague-Dawley
D001786:Blood Glucose; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D005229:Fatty Acids, Monounsaturated; D007534:Isomaltose; C008189:isomaltulose